bioMONTR Labs Announces New Assay for Hepatitis B Pregenomic RNA Quantitation
bioMONTR Labs is pleased to announce that we have completed the analytical validation of our new assay for the detection and quantitation of Hepatitis B pregenomic RNA in chronic HBV (CHB) patients. This first-of-its-kind HBV pgRNA Research Use Only (RUO)…
bioMONTR Labs Announces Laboratory Service Agreement With ViiV Healthcare
bioMONTR Labs reported today they have entered into a new Laboratory Service Agreement with ViiV Healthcare to provide HIV-1 viral load testing services for a recently announced Phase III study with a two-drug of long-acting, injectable regimen of cabotegravir plus rilpivirine in virally…
bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials
bioMONTR Labs announced today they have entered into new Master Service Agreements to provide HIV-1 viral load testing services for CytoDyn’s ongoing Phase 2b PRO 140 Monotherapy Extension Study and their upcoming Phase 3 PRO 140 Monotherapy Study. "We are…